Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eaton Vance Tax-Managed Buy-Write Opportunities Fund

13.78
0.0000
Post-market: 13.890.1099+0.80%17:28 EDT
Volume:96.19K
Turnover:1.33M
Market Cap:1.61B
PE:4.72
High:13.82
Open:13.77
Low:13.77
Close:13.78
Loading ...

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Jul

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Dow Jones
·
03 Jun

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
31 May

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Dow Jones
·
02 May

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 May

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

GlobeNewswire
·
02 Apr

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Dow Jones
·
02 Apr

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Apr

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Mar

Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating

TIPRANKS
·
28 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire
·
07 Feb

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Feb

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire
·
13 Jan

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswire
·
08 Jan